Subscribe for full access
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
2.82
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
#VALUE!
Total Analysts: 16
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
